KAEL-GemVax's GV1001 vaccine shows Phase II promise in lung cancer
This article was originally published in Scrip
Executive Summary
A telomerase peptide oncovaccine being developed by the South Korean group KAEL-GemVax and already in a major Phase III programme for pancreatic cancer has also shown clinical promise in the treatment of non-small cell lung cancer (NSCLC).